ZYMAXID Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zymaxid, and what generic alternatives are available?
Zymaxid is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in ZYMAXID is gatifloxacin. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the gatifloxacin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zymaxid
A generic version of ZYMAXID was approved as gatifloxacin by SANDOZ on July 11th, 2016.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ZYMAXID?
- What are the global sales for ZYMAXID?
- What is Average Wholesale Price for ZYMAXID?
Summary for ZYMAXID
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 108 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,975 |
| Drug Prices: | Drug price information for ZYMAXID |
| What excipients (inactive ingredients) are in ZYMAXID? | ZYMAXID excipients list |
| DailyMed Link: | ZYMAXID at DailyMed |
Recent Clinical Trials for ZYMAXID
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Discover Vision Centers | |
| Toyos Clinic |
Pharmacology for ZYMAXID
| Drug Class | Quinolone Antimicrobial |
Paragraph IV (Patent) Challenges for ZYMAXID
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| ZYMAXID | Ophthalmic Solution | gatifloxacin | 0.5 % | 022548 | 1 | 2010-12-07 |
US Patents and Regulatory Information for ZYMAXID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | ZYMAXID | gatifloxacin | SOLUTION/DROPS;OPHTHALMIC | 022548-001 | May 18, 2010 | AT | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ZYMAXID
See the table below for patents covering ZYMAXID around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 216381 | ⤷ Start Trial | |
| Australia | 3994695 | ⤷ Start Trial | |
| Australia | 694946 | ⤷ Start Trial | |
| Canada | 2208704 | HYDRATE D'ACIDE 8-ALCOXYQUINOLONECARBOXYLIQUE AYANT UNE EXCELLENTE STABILITE ET PROCEDE DE FABRICATION (8-ALKOXYQUINOLONECARBOXYLIC ACID HYDRATE WITH EXCELLENT STABILITY AND PROCESS FOR PRODUCING THE SAME) | ⤷ Start Trial |
| China | 1137890 | ⤷ Start Trial | |
| China | 1171108 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ZYMAXID
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0230295 | C300110 | Netherlands | ⤷ Start Trial | PRODUCT NAME: GATIFLOXACINUM, DESGEWENST IN DE VORM VAN EEN HYDRAAT, ZUURADDITIEZOUT OF ALKALISCH ZOUT, IN HET BIJZONDER GATIFLOXACINUM SESQUIHYDRICUM; REGISTRATION NO/DATE: DE 48870.00.00, 48870.01.00, 48872.00.00, 48872.01.00, 48874.00.00, 48874.01.00, 48876.00.00, 48876.01.00 20011022 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch